Gastrointestinal stromal tumors: Experience in 49 patients

Clinical and Translational Oncology

Volumn 8, Issue 8, 2006, Pages 594-598

  Nieto, Eva Artigau ^a   Aufroy, Alexis Luna ^a   Pórtulas, Elsa Dalmau ^a   Cladera, Pere Rebasa ^a   Fernández, Ruth Orellana ^a   Martin, Ana Darnell ^a   Soto, Salvador Navarro ^a   Pijaume, Carles Pericay ^a  

^a HOSPITAL DE SABADELL   (Spain)

Author keywords

Gastrointestinal stromal tumors; Imatinib; Retrospective; Supervivence

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; INTERCELLULAR ADHESION MOLECULE 1; STEM CELL FACTOR; TUMOR MARKER;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM HEMORRHAGE; DISEASE FREE SURVIVAL; ESOPHAGUS TUMOR; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE OBSTRUCTION; LEIOMYOMA; LEIOMYOSARCOMA; LIVER METASTASIS; MALE; MESENCHYMOMA; MESENTERY TUMOR; NEURILEMOMA; OMENTUM; PERITONEUM TUMOR; RECTUM TUMOR; RETROPERITONEAL TUMOR; RETROSPECTIVE STUDY; SMALL INTESTINE TUMOR; STOMACH TUMOR; SYMPTOMATOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33749063394     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0065-1     Document Type: Article

References (28)

1. Thomas RM, Sobin LH. Gastrointestinal cancer incidence and prognosis by histologic type SEER population-based data 1973-1987. Cancer. 1995;75:154-70.
2. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: Recent advances in understanding of their biology. Hum Pathol. 1999;30:1213-30.
3. Mazur MT, Clark HB. Gastric stromal tumours. Reppraisal of histogenesis. Am J Surg Patol. 1983;7:507-19.
4. Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours. Br J Surg. 2003;90:1178-86.
5. Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumours: Recurrence patterns and proguostic factors for survival. Ann Surg. 2000;231:51-8.
6. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: A sensitive marker for gastrointestinal stromal tumours that is more specific than CD34. Mod Patol. 1998;11:728-34.
7. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumour (GIPACT): Gastrointestinal stromal tumours show phenotypic characteristics of the interstitial cells of Cajal. Am J Patol. 1998;152:1259-69.
8. Demetri GD. Targeting c-kit mutations in solid tumours. Scientific rationale and novel therapeutic opcions. Sem Oncol. 2001; Suppl 17:S19-26.
9. Fletcher C, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensos approach. Hum Pathol. 2002;33:459-65.
10. Fraquemont DW. Differentation and risk assessment of gastrointestinal stromal tumours. Am J Clin Pathol. 1995;103:41-7.
11. El Rifai W, Sarlomo-Rikala M, Anderson LC, et al. DNA sequence copy number changes in gastrointestinal stromal tumors: Tumor progression and prognostic significance. Cancer Res. 2000;60:3899-903.
12. Edmonson J, Marks R, Buckner J, Mahoney MR. Contrast of response to D-MAP+Sargramostim between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Proc Am Soc Clin Oncol. 1999;18:541.
13. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical Management of Gastrointestinal Stromal Tumors: Before and After STI-571. Hum Pathol. 2002;33:466-77.
14. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2185 patients treated with anthracycline-containing first-line regimens. A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol. 1999;17:150-7.
15. Demetri GD, Baker LH, Beech D, et al. NCCN Soft Tissue Sarcomas Practice Guidelines in Oncology V1. 2005.
16. Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal stromal tumors. Current Treatment Options in Oncology. 2001;2(6): 485-91.
17. Poveda A, Maurel J, Martín V. Guía de práctica clínica en los tumores estromales gastrointestinales (GIST). Clinical and Translation Oncology. 2005;7 (extraordinario 2).
18. Hosmer DV, Lemeshow S. Model-building strategies and methods for logistic regression. En Hosmer DV, Applied logistic regression. Nueva York: Wiley and Sons; 2000, p. 91-142.
19. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: Consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol. 2002;33(6):669-76.
20. Peter C, Langerman A, Christopher W, Hart J. Surgical treatment of gastrointestinal stromal tumours in the Imatinib (STI-571) era. Surgery. 2003;134:656-67.
21. Patel SR, Bejamin RS. Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors. Surg Oncol. 2000;9:67-70.
22. Roberts PJ, Eisenberg B. Clinical presentations of gastrointestinal stromal tumours and treatment of operable disease. European of Journal of cancer. 2002;38 Suppl 5:S37-8
23. Casper ES. Gastrointestinal stromal tumors. Curr Treat Options Oncol. 2000;1:267-73.
24. Pierie JP, Choudry U, Muzikansky A, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg. 2001;136:385-9.
25. Carson W, Karakousis C, Douglas H, et al. Results of aggressive treatment of gastric sarcoma. Ann Surg Oncol. 1994;1:244-51.
26. Demetri G, Von Mehren M, Blanke C, et al. Efficacy and safety of inatinib mesylate in advanced gastrointestinal stromal tumors. NEJM. 2002;547(7):472-80.
27. Benjamín RS. Phase III dose-randomized study of imatinib mesylate (ST 1571) for GIST: Intergroup S0033 early results. Proc Ann Meet Am Assoc Clin Oncol. 2003;22:A3271.
28. Verweij J, Casali PG, Zalcberg J, et al. Progresión-free survival in gastrointestinal stromal tumors with high-dose imatinib: Randomized trial. Lancet. 2004;364:1127-34.